Changes in Hong Kong stocks | Rebon Pharmaceutical-B (09637) rose more than 6% Recently, the AP306 global multi-regional phase IIb clinical trial completed the first case of participants were randomly enrolled and administered

The Zhitong Finance App learned that Rebang Pharmaceutical-B (09637) rose by more than 6%. As of press release, it had risen 6.68% to HK$29.06, with a turnover of HK$4.685,600.

According to the news, recently, according to Libang Pharmaceutical's WeChat account, the company announced that the first of its kind, the global phase IIb multi-regional clinical trial (NCT06712654) for patients with hyperphosphatemia undergoing maintenance hemodialysis, has completed the first random enrollment and administration of the first test subjects. The trial is being carried out at various clinical centers in the US and China, and is co-sponsored by Rebon Pharmaceuticals and R1 Therapeutics, Inc. (“R1”).

AP306 (previously EOS789) is a first-of-its-kind oral pan-phosphorus transporter inhibitor. It was first discovered by Chugai Pharmaceutical Co., Ltd. (“Japan Chugai Pharmaceutical”), and the company was authorized to introduce and obtain its global development, production and commercialization rights. Unlike traditional phosphorus binders that mainly bind free intestinal phosphorus, AP306 broadly inhibits three key intestinal phosphorus transporters, NAPI-IIb, PIT-1, and PIT-2, reduces active intestinal phosphorus transport, and explores differentiated treatment routes for the management of hyperphosphatemia. The first test subjects were randomly enrolled and administered, marking that the global development of AP306 has entered a new stage of multi-center clinical implementation in China and the US.